Navigation Links
IDM Pharma Reports 2008 Financial Results
Date:3/31/2009

IRVINE, Calif., March 31 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today reported financial results for the fourth quarter and full year ended December 31, 2008. Financial information presented represents the consolidated results of IDM Pharma, Inc. and its subsidiary, IDM Pharma S.A.

Total revenues in the quarter ended December 31, 2008 were $0.3 million, and net loss was $1.8 million or $0.07 per share for the quarter. Total revenues for the year ended December 31, 2008 were $3.1 million, and net loss was $18.6 million or $0.74 per share for the year. Cash and cash equivalents were $12.8 million as of December 31, 2008 compared to $18.4 million on September 30, 2008 and $28.4 million on December 31, 2007. In order to focus on those areas we believe can provide the most near term value to our stockholders and to ensure we have adequate cash to complete our review of strategic options for the Company, we are concentrating our near-term efforts on certain MEPACT pre-launch commercial activities in Europe and the review of such strategic options, including merger or acquisition opportunities, which may involve a change in control of our company. Consequently, we have placed the U.S. mifamurtide NDA amendment submission on hold until we complete our strategic review, which will allow us to operate into the third quarter of 2009. We have engaged JMP Securities, an investment bank, to advise us in exploring alternatives available to us with respect to a possible merger or acquisition transaction.

"2008 was a significant year for the Company with December's recommendation for approval of MEPACT for the treatment of osteosarcoma in Europe and the formal approval of the centralized marketing authorization following in early March of 2009," said Timothy P. Walbert, president and chief executive officer, IDM Pharma. "W
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors
2. The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health
3. Recent Graduates Finding BioTech & Pharmaceutical Jobs Easier Than Ever With The Launch of CampusRXBio
4. VIA Pharmaceuticals Complies With NASDAQ Rules
5. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
6. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
8. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
9. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
10. Isis Pharmaceuticals to Present at the 4th Annual Citi Biotech Day
11. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015 GliaCure, ... of novel therapies for neurological and neuropsychiatric disorders ... initiated dosing of Alzheimer,s patients in a Phase ... GC021109, a compound developed as a potential disease-modifying ... is innovative in that it both promotes the ...
(Date:5/4/2015)... TORONTO , May 4, 2015 /PRNewswire/ - ... pleased to announce the appointment of Dr. Roger ... extensive experience guiding biotech companies in matters including ... Fluorinov,s leadership team and adds significant regulatory expertise ... Dr. Garceau brings 30 years of pharmaceutical ...
(Date:5/4/2015)... Genedata, a leading provider of advanced ... research, today announced the release of Genedata ... enterprise solution for biologics R&D. This first-in-class workflow ... and development of novel biotherapeutics. Version 5.0 enables ... optimization and developability requirements. Genedata will present highlights ...
(Date:5/4/2015)... -- China Cord Blood Corporation (NYSE: CO ) ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has been informed that Golden ... Kong listed company and a substantial shareholder ... "Agreement") to purchase the Company,s outstanding 7% senior convertible ...
Breaking Biology Technology:GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 2China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 3
... 18 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ... Society of Clinical Oncology (ASCO) Annual Meeting being held ... to our product candidates Stimuvax(R), PX-866 and PX-12 are ... Web site, www.abstract.asco.org ., Abstracts ...
... MEDIA ALERTWASHINGTON, May 18 Focusing on ... essential to reducing preventable adverse events, and ... change, influential leaders will gather at the ... to discuss the fundamental shifts necessary to ...
... Paragon Bioservices, Inc., a contract research and manufacturing organization ... Supplier Award for exceptional performance in support of Lilly,s ... in this manner by such an elite organization and ... of quality, excellence and superior customer service in the ...
Cached Biology Technology:Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting 2Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting 3Healthcare Leaders to Address Patient Safety and Reform at the National Patient Safety Foundation Congress, Washington, DC, May 20-22 2Healthcare Leaders to Address Patient Safety and Reform at the National Patient Safety Foundation Congress, Washington, DC, May 20-22 3
(Date:4/2/2015)... -- Fingerprint Cards (FPC) has received an ... distributor World Peace Industrial Group (WPI), part of WPG ... major part of the shipments will take place during ... manufacturers in China . The order ... revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:3/31/2015)... , March 31, 2015   Guidepoint , a ... of the Post-Surgical Pain Management TRACKER, part of the ... usage trends in the medical device and therapeutics markets. ... data including treatment volumes, market share, and adoption rates ... associated with joint surgery. The Post-Surgical Pain ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and Markets ... "Face and Voice Biometrics - Global Strategic Business Report" report ... for Face and Voice Biometrics in US$ Thousands by the following ... analytics for the US, Canada , ... , Middle East & ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... by Johns Hopkins scientists has,found the first clear ... remarkable ability to recognize and respond to a ... of genes whose,only apparent function is to jump ... themselves out of the genetic material, and scientists,have ...
... Fast-track recruitment has begun for a trial to investigate ... the National Institute of Allergy and Infectious Diseases (NIAID), ... today. , Sites in Rochester, NY, Baltimore and Los ... The clinical sites are part of the NIAID-sponsored Vaccine ...
... Roger Brent, President and Director of Research at ... announced today ,the release of a new approach ... 2005 edition of Nature,Biotechnology.,The research article, entitled ... 1.0" (pdf) ,describes MSI's discrete stochastic event simulator, ...
Cached Biology News:Gene sequencing explains bioremediation 'bug' 2Gene sequencing explains bioremediation 'bug' 3NIAID Initiates Trial of Experimental Avian Flu Vaccine 2MSI releases 'moleculizer' - a new approach to simulation of intracellular biochemical networks 2MSI releases 'moleculizer' - a new approach to simulation of intracellular biochemical networks 3
Amino Acid Analysis is performed using ion-exchange separation of the amino acids from acid hydrolysates, followed by ninhydrin detection. Typical quantities required are 0.1 to 0.5 mg, depending on...
...
ANTI CORTIS BIN GLOB...
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
Biology Products: